AngioDynamics(ANGO) ZACKS·2025-04-03 18:15Core Viewpoint - AngioDynamics, Inc. reported better-than-expected results for the third quarter of fiscal 2025, with adjusted earnings per share (EPS) of 3 cents, compared to a loss of 16 cents in the same quarter last year and a consensus estimate of a loss of 13 cents [1][18]. Financial Performance - Adjusted loss per share on a pro-forma basis was 8 cents, improved from 16 cents year-over-year [2]. - GAAP loss per share was 11 cents, significantly better than the loss of $4.67 reported in the prior year [2][3]. - Total revenues for the fiscal third quarter were $72 million, down 4.2% year-over-year but exceeding the Zacks Consensus Estimate by 2% [4]. - On a pro forma basis, net sales were $72 million, reflecting a 9.2% increase year-over-year [4]. Revenue Breakdown - U.S. net revenues were $61.3 million, down 1.6% year-over-year, but up 9.9% on a pro forma basis [6]. - International revenues totaled $10.7 million, down 16.9% year-over-year on a reported basis, but up 5.1% on a pro forma basis [7]. Segment Analysis - Med Tech revenues were $31.3 million, up 21.3% year-over-year, surpassing projections [8][9]. - Med Device revenues were $40.7 million, down 17.6% from the previous year, but up 0.9% on a pro forma basis [11]. Margin and Expense Analysis - Pro forma gross profit increased by 15.4% year-over-year to $38.9 million, with gross margin expanding by 290 basis points to 54% [12]. - Sales and marketing expenses rose by 7.9% to $25.5 million, while R&D expenses decreased by 14.4% to $6.9 million [13]. Cash Position - The company ended the quarter with cash and cash equivalents of $44.8 million, down from $54.1 million in the previous quarter, and had no debt [15]. Guidance - AngioDynamics revised its fiscal 2025 guidance, expecting net sales between $285 million and $288 million, indicating growth of 5.3-6.4% from the previous year [16]. - Adjusted loss per share is now projected to be between 31 cents and 34 cents, an improvement from earlier estimates [17].